Aprea Therapeutics, INC Form 4 insider transactions

Director Michael Grissinger received a grant of restricted stock units and stock options as part of his board compensation.

Director Gabriela Gruia was granted 3,135 restricted stock units and 12,555 stock options by Aprea Therapeutics.

Director Richard Peters received a grant of restricted stock units and stock options as part of annual board compensation.

Director John B. Henneman III was granted restricted stock units and stock options as part of board compensation.

Director Jean-Pierre Bizzari received a grant of restricted stock units and stock options as part of board compensation.

Director Marc Duey acquired 3,135 restricted stock units and 12,555 stock options as part of an annual compensation grant.

Director Rifat Pamukcu was granted 3,135 restricted stock units and 12,555 stock options as part of board compensation.

Director Bernd R. Seizinger was granted 3,135 restricted stock units and 12,555 stock options by Aprea Therapeutics.

Aprea Therapeutics' Senior VP and CFO, John P. Hamill, acquired pre-funded and common warrants in a private placement, signaling insider confidence.

Aprea Therapeutics director and 10% owner Richard Peters acquired pre-funded and common warrants in a private placement.

Aprea Therapeutics' President and CEO, Oren Gilad, acquired 20,175 restricted stock units and 80,700 stock options, increasing his beneficial ownership in the company.

Aprea Therapeutics' Senior VP and CFO, John P. Hamill, acquired 10,095 restricted stock units and 40,380 stock options, signaling continued alignment with shareholder interests.

Aprea Therapeutics' President and CEO, Oren Gilad, acquired 28,100 shares and accompanying warrants in a private placement, signaling confidence.

Aprea Therapeutics' SrVP/CFO John P. Hamill acquired 5,700 shares of common stock and accompanying warrants in a private placement.

Aprea Therapeutics Director Marc Duey acquired 21,459 shares of common stock and an equal number of warrants in a private placement.

Aprea Therapeutics' SrVP/CFO, John P. Hamill, acquired 5,000 shares of common stock and 5,000 common warrants in a private placement on December 10, 2025.

Aprea Therapeutics CEO and President Oren Gilad acquired pre-funded and common warrants through a private placement, increasing his beneficial ownership.

Aprea Therapeutics, Inc. Director John B. Henneman III was granted 1,045 restricted stock units and 4,185 stock options as part of his compensation, aligning his interests with shareholders.

Aprea Therapeutics, Inc. Director Bernd R. Seizinger was granted 1,045 restricted stock units and 4,185 stock options on June 5, 2025, as part of his compensation.

Aprea Therapeutics Director Richard Peters was granted 1,045 restricted stock units and 4,185 stock options on June 5, 2025, increasing his beneficial ownership in the company.

Aprea Therapeutics, Inc. Director Rifat Pamukcu was granted 1,045 restricted stock units and 4,185 stock options, aligning his interests with shareholders.

Aprea Therapeutics, Inc. Director Gabriela Gruia reported the acquisition of 1,045 restricted stock units and 4,185 stock options on June 5, 2025, aligning her interests with shareholders.

Aprea Therapeutics, Inc. Director Michael Grissinger acquired 1,045 restricted stock units and 4,185 stock options on June 5, 2025, as reported in a recent SEC Form 4 filing.

Aprea Therapeutics, Inc. Director Marc Duey reported the acquisition of 1,045 restricted stock units and 4,185 stock options on June 5, 2025, as part of his compensation.

Aprea Therapeutics, Inc. Director Jean-Pierre Bizzari was granted 1,045 restricted stock units and options to purchase 4,185 shares of common stock on June 5, 2025, as part of his compensation.

Aprea Therapeutics' CEO, Oren Gilad, recently acquired additional shares of the company's common stock through open market purchases.

John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, acquired shares and stock options on March 27, 2025.

Aprea Therapeutics' CEO, Oren Gilad, reports acquisition of common stock and stock options, along with existing holdings.

Director Marc Duey sold 6,462 shares of Aprea Therapeutics common stock on October 18, 2024, due to an insufficient cash position in his brokerage account, resulting in a short-swing transaction requiring him to pay the company $1,558.05.

Aprea Therapeutics' CEO, Oren Gilad, recently purchased 500 shares of the company's common stock at an average price of $3.915 per share.